Grifols, S.A. (GRFS) Stock Price & Analysis
Grifols, S.A. (GRFS) closed at USD 7.45 on Thursday, October 22, 2026, down 0.67% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 7.45; the Oct 22, 2026 session ranged USD 7.37–7.49 on volume of 482,545 shares. Market capitalization is —, with a 52-week range of USD 6.96–9.9 (NMS). Source: Nexqual, retrieved October 23, 2026 at 11:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GRFS.md
Key facts (GRFS)
- Total return with dividends: 1Y -20.9% vs S&P 500 +14.9%; 5Y -44.2% vs S&P 500 +80.3%.
- Next earnings: 2026-07-28, EPS estimate USD 0.3, revenue estimate $1.99B.
Total return (dividends reinvested) (GRFS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -20.9% | -44.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -21.0% | -11.0% |
| Volatility (annualized) | 32.0% | 49.1% |
| Max drawdown | -27.2% (Feb 2026→Jun 2026) | -55.8% (Oct 2021→Oct 2022) |
GRFS suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Siemens | “In connection with the termination, we entered into a new multi-year Exclusive Supply Agreement with Ortho under which we continue to manufacture and supply antigens to Ortho, as well as to third parties including Abbott Laboratories, Siemens and OraSure Technologies.” |
| Supplier | Grifols Canada Plasma | “In addition to plasma collected at Grifols Canada Plasma's centers, we fulfill this agreement with other plasma collected from a Canada-based plasma collection center network owned and managed by us, manufacturing our products in our facility in Montreal, Quebec (described below).” |
| Supplier | Haema GmbH and BPC Plasma | “Although we currently do not hold any equity interests in either Haema GmbH or BPC Plasma Inc., we retain control over such entities due to, among other factors, (1) the call option agreement to reacquire their shares and the financial capability to exercise such call option, (2) potential voting rights derived from the call option, (3) the fact that we acquire all of the plasma collected in the plasma collection …” |
| Supplier | Haema | “Although we currently do not hold any equity interests in either Haema GmbH or BPC Plasma Inc., we retain control over such entities due to, among other factors, (1) the call option agreement to reacquire their shares and the financial capability to exercise such call option, (2) potential voting rights derived from the call option, (3) the fact that we acquire all of the plasma collected in the plasma collection …” |
| Supplier | BPC Plasma | “Although we currently do not hold any equity interests in either Haema GmbH or BPC Plasma Inc., we retain control over such entities due to, among other factors, (1) the call option agreement to reacquire their shares and the financial capability to exercise such call option, (2) potential voting rights derived from the call option, (3) the fact that we acquire all of the plasma collected in the plasma collection …” |
| Customer | Alpha Therapeutic | “In 2024, net revenue from our albumin sales increased by 7.1% (8.0% at constant currency) as compared to 2023, continuing to see increased demand across China and the U.S. Net revenue from sales of Alpha-1 and specialty proteins increased by 4.1% (4.9% at constant currency) in 2024 as compared to 2023.” |
| Partner | Scranton Plasma | “Also on December 28, 2018, we entered into a call option agreement with Scranton Plasma B.V. whereby we may repurchase the shares of Haema GmbH and BPC Plasma Inc. at any time.” |
| Partner | Canadian Plasma Resources | “Through an agreement with Grifols Canada Plasma (formerly named Canadian Plasma Resources Corporation) we have the right to obtain plasma donated at collection centers owned by Grifols Canada Plasma.” |
| Partner | AESKU Diagnostics | “Pursuant to an exclusive agreement with AESKU Diagnostics GmbH & Co. ("AESKU"), we distribute autoimmunity diagnostic products in Chile, Mexico, Portugal and Spain.” |
| Partner | Immunotek GH | “Pursuant to this collaboration agreement, we formed ITK JV, a joint operation company through which we initially held a 75% interest in each of the 28 plasma collection centers, while ImmunoTek held the remaining 25%.” |
| Partner | Scranton Enterprises | “On July 29, 2025, we entered into a sponsorship agreement with Club Joventut Badalona, S.A.D., an entity in which Scranton Enterprises B.V. (one of our major shareholders) is the majority shareholder.” |
| Partner | Biomat USA | “In November 2021 approval was received from the pertinent authorities to close the agreement with GIC (Sovereign Fund of Singapore), announced in June 2021, whereby the Group received an amount of US Dollars 990 million in exchange for 10 ordinary Class B shares in Biomat USA and nine ordinary Class B shares in a new sub-holding, Biomat Newco, created for this purpose.” |
Quoted from the company's 20-F filed Apr 17, 2026.
GRFS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.30 | $0.29 | +3.5% | $1.99B | 1 |
| Next quarter (ends Dec 2026) | $0.39 | $0.33 | +18.3% | $2.17B | 1 |
| Current fiscal year (ends Dec 2026) | $1.16 | $1.06 | +9.3% | $7.68B | 2 |
| Next fiscal year (ends Dec 2027) | $1.44 | $1.45 | -0.3% | $8.16B | 2 |
GRFS options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 62.1% | ±13.7% |
| Dec 18, 2026 | 56 | 77.1% | ±21.7% |
| Feb 19, 2027 | 119 | 33.8% | ±22.8% |
| May 21, 2027 | 210 | 43.2% | ±45.2% |
30-day implied volatility 32.2% vs 23.4% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 11:22 UTC)
| Price | USD 7.45 |
|---|---|
| Change | ▼ 0.67% (down) |
| Previous Close | USD 7.45 |
| Open | USD 7.45 |
| Day Range | USD 7.37 – 7.49 |
| 52-Week Range | USD 6.96 – 9.9 |
| Volume | 482,545 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (GRFS)
Nexqual's technical model rates GRFS "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 11:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.6 (neutral) |
| vs SMA50 | Below (USD 7.58) |
| MACD | -0 (negative) |
Earnings (GRFS)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 0.3 |
| Revenue Estimate | $1.99B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.17 vs est 0.28 ▼ miss |
Source: Nexqual, October 23, 2026 at 11:22 UTC.
Financials & Fundamentals (GRFS)
| Total Revenue | $7.42B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -0.90% |
| Gross Margin | +37.79% |
| Operating Margin | +15.90% |
| Profit Margin | +6.09% |
| ROE | +6.93% |
| Debt / Equity | 1.17 |
| Current Ratio | 2.37 |
| Total Cash | $537.00M |
| Total Debt | $9.36B |
Source: Nexqual, October 23, 2026 at 11:22 UTC.
Ownership (GRFS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +57.27% |
| Shares Outstanding | 258.22M |
| Float | 836.45M |
Source: Nexqual, October 23, 2026 at 11:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OGN | Organon & Co. | USD 13.75 | ▲ 0% |
| BIIB | Biogen Inc. | USD 253.84 | ▲ 5.34% |
| SNY | Sanofi | USD 41.96 | ▲ 2.42% |
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt